Pharmacy benefit managers and health carriers required to use prescription drug rebates and other compensation to benefit covered persons, and report required.
Impact
This legislation is expected to have significant implications for state laws governing pharmacy benefit managers and health insurance practices. By mandating the direct application of compensation to reduce costs for consumers, HF1711 seeks to enhance transparency in drug pricing and alleviate the financial burden on individuals who rely on prescription medications. The requirement for annual reporting from PBMs and health carriers to demonstrate compliance ensures ongoing accountability and oversight in the administration of prescription drug benefits.
Summary
House File 1711 (HF1711) is a legislative proposal aimed at ensuring that pharmacy benefit managers (PBMs) and health carriers are required to use any received compensation related to prescription drugs to benefit covered persons directly. The bill mandates that these entities remit all financial benefits received from drug manufacturers to the covered persons at the point of sale, thereby reducing their out-of-pocket costs for medications. The bill has an effective date of January 1, 2024, establishing clear responsibilities for managing prescription drug costs in the healthcare system.
Contention
Notable points of contention surrounding HF1711 include concerns over the operational impact on pharmacy benefit managers and health carriers, who may face challenges adapting their business models to comply with the new requirements. Proponents of the bill argue that it promotes consumer welfare and reduces unnecessary costs, while critics may voice concerns about potential increases in premiums or reduced provider options as a result of tighter regulations. The discussion points to a broader debate on how to balance the interests of consumers, healthcare providers, and pharmaceutical companies within the state’s regulatory framework.
Similar To
Pharmacy benefit managers and health carriers requirement to use prescription drug rebates and other compensation to benefit covered persons